Genzyme ran into a snag in April when the US Food and Drug Administration (FDA) rejected its application to produce Myozyme (alglucosidase alfa, rhGAA) in its 2,000–liter-scale facility under ...

Sanofi's Genzyme rare diseases division already sells ... which remains the only other FDA-approved therapies for Pompe. The company estimates there are around 3,500 people in the US with both ...

Sanofi paid out $315 million to former Genzyme shareholders in that case, well below the $700 million to $3.8 billion range promised in the CVR. The FDA is set to decide on MSD's Keytruda as ...

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

Readers respond to Nicholas Kristof’s column about his friend’s struggle with addiction. To the Editor: Re “The Prison Sentence That Saved My Friend’s Life,” by Nicholas Kristof (column ...

L Becquemont received consulting fees from Sanofi-Aventis, Pfizer and Servier, and lecture fees from Genzyme, GlaxoSmithKline, Bristol-Myers Squibb and Merck Sharp and Dohme. His wife works for ...

Skin is the largest organ of human body, acting as a barrier with protective, immunologic and sensorial functions. Its permanent exposure to the external environment can result in different kinds ...

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. A sustained ...